뉴스벤징가
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback
· 발표
기사 요약
Tenax Therapeutics announced Phase 3 LEVEL trial results for TNX-103, missing primary endpoints while showing subgroup benefits.
기사 원문에서 발췌했어요.뉴스 본문을 불러오고 있어요.
Tenax Therapeutics announced Phase 3 LEVEL trial results for TNX-103, missing primary endpoints while showing subgroup benefits.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…